Drug Profile
Research programme: antibacterials - GPC Biotech
Alternative Names: Antibacterials research programme - GPC BiotechLatest Information Update: 10 May 2004
Price :
$50
*
At a glance
- Originator GPC Biotech AG
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 10 May 2004 This antibacterials research programme is available for licensing (http://www.gpc-biotech.com)
- 31 Dec 2003 The licensing agreement between GPC Biotech and PanTherix has been terminated
- 31 Dec 2003 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)